prIME LINES BRAF-rechallenge-for-metastatic-melanoma

Pembrolizumab, Another Adjuvant Treatment Option for Resected Stage III Melanoma

In recent years, immunotherapy and targeted therapy (for BRAF positive) have emerged as potential adjuvant therapy options for patients with high-risk stage III melanoma following resection. The first of these agents approved for high-risk resected melanoma was the CTLA-4 inhibitor ipilimumab. This was based on improved survival rates compared to placebo, though at the expense[…]

Read More

Cancer_wrecking_ball

First-Line Combination of Pembrolizumab and Platinum/Pemetrexed Chemotherapy Improves Survival in Nonsquamous Non-Small Cell Lung Cancer

For patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, the standard of care has historically been chemotherapy. Due to survival benefit and a favorable toxicity profile, immunotherapy with the PD-1 inhibitor pembrolizumab offers an attractive alternative to first-line chemotherapy, but only for patients with PD-L1 expression >50%.[…]

Read More

biosimilars, immunotherapy, mesothelioma, CML

Four Oncology Articles Worth Reading

HER2 As a Target in Colorectal Cancer. Approximately 5% of RAS wildtype colorectal cancers (CRC) are driven by mutations or amplification of human epidermal growth factor 2 (HER2), providing an opportunity for HER2-targeted therapy in this subset of patients. Presence of this biomarker can potentially predict lack of benefit to anti-EGFR monoclonal antibodies. This review[…]

Read More

malignant pleural effusion

Outpatient Talc Administration Through Indwelling Pleural Catheter Effective for Managing Malignant Pleural Effusion

Malignant pleural effusions occur in up to 750,000 patients with malignant cancer each year, and are associated with debilitating symptoms requiring frequent intervention. The most successful treatment for malignant pleural effusion is inducing pleurodesis through talc administration. While this is an effective treatment, it requires hospitalization for up to a week.  An alternative outpatient option[…]

Read More

Prescription_with_food_primelines

Can Low-Dose Abiraterone Taken With Food Replace Standard Abiraterone Dosing in Castration-Resistant Prostate Cancer?

Abiraterone acetate is a standard first-line therapy for men with metastatic castration-resistant prostate cancer (CRPC), and is the most common prostate cancer treatment prescribed in the United States. While the standard dose of abiraterone 1000 mg is taken under fasting conditions, early studies indicated a potential increase in drug exposure when abiraterone was administered with[…]

Read More

FDA, breast cancer, lung cancer, prostate, abemaciclib, durvalumab, apalutamide

FDA Approves Three Agents for Hematologic Malignancies in March

• Blinatumomab Received Accelerated Approval for Minimal Residual Disease–Positive ALL. On 29 March the United States Food and Drug Administration (FDA) expanded the indication of the CD19/CD3 bispecific T-cell engager blinatumomab (Blincyto®, Amgen) to include adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission (CR) with minimal[…]

Read More

Cancer-immunotherapy

Efficacy of Avelumab in Newly Diagnosed Metastatic Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with few treatment options and poor prognosis, particularly in patients with metastatic disease. Until recently, chemotherapy was the only first-line treatment option. Despite high initial responses to chemotherapy, responses are usually of a short duration (2.8 months – 8 months), and chemotherapy is associated[…]

Read More

prIME LINES RCC_kidney cross section

Nivolumab and Ipilimumab Combination Improves Survival in Intermediate/Poor-Risk Renal Cell Carcinoma

For the majority of patients with advanced clear cell renal cell cancer (RCC), initial treatment includes an angiogenesis-targeting therapy, such as the multikinase tyrosine kinase inhibitor (TKI) sunitinib. However, despite the notable efficacy of multikinase inhibitors, responses to these agents are usually not durable, and complete responses are rare. Immunotherapy with immune checkpoint inhibitors has[…]

Read More

rectal cancer

Total Neoadjuvant Therapy, A Standard of Care for High-Risk Locally Advanced Rectal Cancer

For patients with locally advanced rectal cancer, the current treatment involves chemoradiation (chemoRT) followed by surgery and adjuvant chemotherapy with fluorouracil and oxaliplatin. While this treatment strategy results in excellent local control, many patients eventually develop distant recurrence. Total neoadjuvant therapy (TNT), in which induction chemotherapy prior to chemoRT is given in place of postoperative[…]

Read More

leukemic cell

Long-Term Clinical Benefit With Ponatinib in Heavily Pretreated Chronic Phase Chronic Myeloid Leukemia

Ponatinib is a potent third-generation tyrosine kinase inhibitor (TKI) with activity against both native and mutant BCR-ABL kinases, including T315l, which is resistant to other TKIs. Based on results from the pivotal phase II PACE trial (N = 449) ponatinib was approved in 2012 for treatment of patients with chronic myeloid leukemia (CML) and Philadelphia[…]

Read More